Go to content
Koninklijke Philips N.V.

Koninklijke Philips N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 07 jan 2010 - 08:01
Statutaire naam Koninklijke Philips N.V.
Titel Philips and bioMérieux announce partnership to develop and market next-generation handheld diagnostic solutions for point-of-care
Bericht January 7, 2010 PHILIPS AND BIOMÉRIEUX ANNOUNCE PARTNERSHIP TO DEVELOP AND MARKET NEXT-GENERATION HANDHELD DIAGNOSTIC SOLUTIONS FOR POINT-OF-CARE Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals. Amsterdam, The Netherlands, Marcy l’Etoile, France – Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)). “Philips is convinced that point-of-care testing in hospital critical care settings will play a major part in improving patient outcomes and reducing healthcare costs. It is an excellent fit with our leading market position in critical care settings and our holistic care cycle approach to, for example, cardiac care,” said Steve Rusckowski, Executive Vice President and Chief Executive Officer, Philips Healthcare. “Their combined knowledge of medical technology, biomarker assays and clinical workflows, coupled with their joint understanding of the relevant markets, stakeholders and channels, puts Philips and bioMérieux in a commanding position to drive forward a paradigm change in critical care decision-making.” “We are very pleased to be partnering with Philips, which has a strong tradition in innovating patient care, and our collaboration will result in superb products able to rapidly deliver high medical value results to clinicians,” said Stéphane Bancel, bioMérieux Chief Executive Officer. “We will be leveraging the strong synergies between our VIDAS® biology expertise and Philips’ unique engineering and technology capabilities. This

Datum laatste update: 12 juni 2024